Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

  1. Aix, S.P.
  2. Ciuleanu, T.E.
  3. Navarro, A.
  4. Cousin, S.
  5. Bonanno, L.
  6. Smit, E.F.
  7. Chiappori, A.
  8. Olmedo, M.E.
  9. Horvath, I.
  10. Grohé, C.
  11. Farago, A.F.
  12. López-Vilariño, J.A.
  13. Cullell-Young, M.
  14. Nieto, A.
  15. Vasco, N.
  16. Gómez, J.
  17. Kahatt, C.
  18. Zeaiter, A.
  19. Carcereny, E.
  20. Roubec, J.
  21. Syrigos, K.
  22. Lo, G.
  23. Barneto, I.
  24. Pope, A.
  25. Sánchez, A.
  26. Kattan, J.
  27. Zarogoulidis, K.
  28. Waller, C.F.
  29. Bischoff, H.
  30. Juan-Vidal, O.
  31. Reinmuth, N.
  32. Dómine, M.
  33. Paz-Ares, L.
  34. Show all authors +
Journal:
The Lancet Respiratory Medicine

ISSN: 2213-2619 2213-2600

Year of publication: 2023

Volume: 11

Issue: 1

Pages: 74-86

Type: Article

DOI: 10.1016/S2213-2600(22)00309-5 GOOGLE SCHOLAR

Sustainable development goals